Efficacy and Safety of High Doses of Safinamide in Advanced Parkinson’s Disease Patients in a Real-World Experience
Objective: To evaluate in a real-world experience high doses of safinamide in patients with fluctuating Parkinson's disease (PD). Background: Standard doses of safinamide (50-100 mg)…Inhaled levodopa (LD) as a treatment for Parkinson’s disease (PD) patients in an emergency setting
Objective: To report on use of CVT-301 (inhaled LD) to treat PD patients with complicated OFF period symptoms who present to the emergency department (ED).…Topographical subtypes of multiple system atrophy: MRI and PET studies
Objective: To investigate the MSA subtypes based on the topography of MSA lesions, employing MRI, PET with [18F]FP-CIT and [18F]FDG PET. Background: Based on the…Camptocormia in patients with multiple system atrophy with different disease durations
Objective: The aims of this study were to explore the prevalence of and factors associated with camptocormia in a cohort of multiple system atrophy (MSA)…FDG-PET degeneration patterns predict amyloid deposition in Corticobasal Syndrome
Objective: To investigate if an individual clinically-focused analysis of brain FDG-PET metabolic patterns and a comprehensive neurological evaluation could distinguish Corticobasal Syndrome (CBS) pathological variants…Potential Diagnosis Biomarks in Serum Biochemical items of Vascular Parkinsonism Patients
Objective: Evaluating the serum biochemical items for diagnosis of vascular parkinsonism. Background: Currently, the most effective diagnostic methods for VP are mainly based on clinical symptoms.…Circadian rhythm alterations in an in vitro cellular model of Spinocerebellar ataxia type 17
Objective: To study in vitro expression of circadian rhythm genes (CLOCK, BMAL) in fibroblasts and neural cells of SCA17 patients. Background: Spinocerebellar Ataxia 17 (SCA17)…Does “5-2-1” identify patients with suspected Advanced Parkinson’s Disease? Evidence of clinical accuracy from G7 countries
Objective: Evaluate the psychometric properties of (i) the “5-2-1” criteria and (ii) consensus-driven clinical indicators of suspected advanced Parkinson’s disease (APD). Background: Recent consensus panel…The utility of single dose levodopa challenges in the management of Parkinson’s disease
Objective: To retrospectively review the clinical utility of single dose levodopa challenges in the management of Parkinson in a tertiary movement disorder clinic. Background: Acute…Cross-linguistic exploration of speech treatment for Parkinson’s disease: is a universal speech treatment approach plausible?
Objective: Examine speech treatment outcomes in people with Parkinson’s disease (PD) across different languages to explore the plausibility of a universal speech treatment approach. Background:…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.